With its high tumor accumulation and ideal biosafety (Fig. 4b–d, Supplementary Figs. 13, 15, 16), SPNpro enabled targeted degradation of IDO in the tumor of living mice, leading to localized immunometabolism intervention. Here, IDO1 is linked to neoplasm.